Hosted by the Biotechnology Market Organization.

– 3:30 p.m. Speakers Consist of: Anne Montgomery, BioProcess International; Laura Bush, Advanstar Communications; Parrish Galliher, M.S., Xcellerex, Inc; Steven Lee, Ph.D., A-Bio Pharma Pte Ltd.; Alain Pralong, Crucell NV; Eric Langer, Ph.D., BioPlan Associates, Inc.m. – 3:30 p.m.D., Caris and Company; Joe Shaw, Syntiron; Gavin Zealey, MBA, sanofi Pasteur; Vijay Samant, Ph.D., Vical Inc.; Jan ter Meulen, M.D., Merck; James Jackson, Ph.D., Emergent BioSolutions, Inc. It’s Personal – Transforming HEALTHCARE through Personalized Medication Tuesday, May 4, 4:00 p.m. – 5:30 p.m. Loudspeakers Include: Edward Abrahams, Ph.D., Personalized Medication Coalition; Linh Hoang, M.D., Life Technology; Laura Shawver, Ph.D., The Clearity Basis; Felix Frueh, MEDCO; Nicholas Dracapoli, Johnson & Johnson Pharmaceuticals Pandemic Preparedness: Therapeutics Plan and Deployment Wednesday May 5, 10:00 a.m.Hay, Ph.D., and Donna M. Ambrosino, M.D.: Treatment with Monoclonal Antibodies against Clostridium difficile Toxins In the past decade, there’s been a striking upsurge in the prevalence of Clostridium difficile contamination and in linked mortality in the United States, Canada, and Europe.1-5 The widespread usage of broad-spectrum antibiotics places patients at an increased risk for C. Difficile diarrhea or colitis and offers changed the epidemiology of C. Difficile infection. This has been seen as a the emergence of a hypervirulent strain of C. Difficile and an increasing risk of treatment failure and recurrent infection.1,6-14 We developed one fully individual monoclonal antibody targeted against C. Difficile toxin A and a second against toxin B . We have found significant efficacy for the mixed antibodies within an established hamster style of C.